{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:57:32Z","timestamp":1789131452326,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T02:14:17Z","timestamp":1714788857000},"page":"592-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians"],"prefix":"10.1016","volume":"24","author":[{"given":"Tommaso","family":"Lupia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-541X","authenticated-orcid":false,"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.05.002_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0002","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haemat"},{"key":"10.1016\/j.clml.2024.05.002_bib0003","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.05.002_bib0004","unstructured":"FDA. FDA approves idecabtagene vicleucel for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma. Accessed June 2 ,2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0005","unstructured":"EMA. First cell-based gene therapy to treat adult patients with multiple myeloma. https:\/\/www.ema.europa.eu\/en\/news\/first-cell-based-gene-therapy-treat-adult-patients-multiple-myeloma. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0006","unstructured":"FDA. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0007","unstructured":"EMA. New gene therapy to treat adult patients with multiple myeloma. https:\/\/www.ema.europa.eu\/en\/news\/new-gene-therapy-treat-adult-patients-multiple-myeloma. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0008","unstructured":"FDA. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0009","unstructured":"EMA. New medicine for multiple myeloma patients with limited treatment options. https:\/\/www.ema.europa.eu\/en\/news\/new-medicine-multiple-myeloma-patients-limited-treatment-options. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0010","unstructured":"FDA. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0011","unstructured":"EMA. New treatment option for heavily pre-treated multiple myeloma patients. https:\/\/www.ema.europa.eu\/en\/news\/new-treatment-option-heavily-pre-treated-multiple-myeloma-patients. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0012","unstructured":"FDA. FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0013","unstructured":"Janssen. European Commission Approves talvey (talquetamab), J. N. B. T. for the T. of P. with R. and R. M. M. https:\/\/www.janssen.com\/it\/node\/72261. Accessed June 2, 2024."},{"key":"10.1016\/j.clml.2024.05.002_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.05.002_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0016","doi-asserted-by":"crossref","unstructured":"Lin Y., Martin T.G., Usmani S.Z., et al. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. 8009 Poster Discussion Session. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"10.1016\/j.clml.2024.05.002_bib0017","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0020","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0021","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2024.05.002_bib0022","doi-asserted-by":"crossref","first-page":"AB224","DOI":"10.1016\/j.jaci.2022.12.698","article-title":"Hypogammaglobulinemia and risk of infectious complications in patients receiving idecabtagene vicleucel","volume":"151","author":"Barmettler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2024.05.002_bib0023","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.05.002_bib0024","series-title":"The 65th ASH annual meeting abstracts oral abstracts 705.cellular immunotherapies: late phase and commercially available therapies real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T cell therapy for relapsed\/refractory multipleblood","volume":"142","author":"Surbhi","year":"2023"},{"key":"10.1016\/j.clml.2024.05.002_bib0025","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0026","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.clml.2024.05.002_bib0027","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.clml.2023.08.012","article-title":"Ciltacabtagene autoleucel in patients with prior allogeneic stem cell transplant in the CARTITUDE-1 study","volume":"23","author":"Htut","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.05.002_bib0028","article-title":"8012 Poster discussion session safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-Cel) for relapsed\/refractory multiple myeloma","author":"Hansen","year":"2023","journal-title":"RRMM"},{"key":"10.1016\/j.clml.2024.05.002_bib0029","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.clml.2024.05.002_bib0030","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"8011 poster discussion session long-term follow-up from majesTEC-1 of Teclistamab, a B-cell maturation antigen (bcma) x cd3 bispecific antibody","volume":"41","author":"Van De Donk","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2024.05.002_bib0031","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2023-182130","article-title":"Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"142","author":"Tomasson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), A BCMA \u00d7 CD3 T-cell engager, in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study","volume":"7","author":"Wong","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.05.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967700.16100.68","article-title":"S197 LINKER-MM1 study: LINVOSELTAMAB (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.05.002_bib0034","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen 3 CD3 bispecific t-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0036","series-title":"Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","article-title":"8011 poster discussion session long-term follow-up from majesTEC-1 of teclistamab, a B-Cell maturation antigen (BCMA) x CD3 bispecific antibody","author":"Van De Donk","year":"2023"},{"key":"10.1016\/j.clml.2024.05.002_bib0037","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.05.002_bib0038","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2021-148723","article-title":"plasma cell dyscrasias: clinical-prospective therapeutic trials subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed\/refractory multiple myeloma: results from a phase 1b multicohort study","volume":"138","author":"Rodriguez-Otero","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0039","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of majesTEC-2, a phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.05.002_bib0041","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2023-180421","article-title":"Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0042","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0043","doi-asserted-by":"crossref","unstructured":"Raje, N.S., Leleu X.P., Lesokhin A.M., et al., 8040 poster session efficacy and Safety of elranatamab by age and frailty in patients (Pts) with relapsed\/refractory multiple (RRMM): a subgroup analysis from magnetisMM-3. (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.8040"},{"key":"10.1016\/j.clml.2024.05.002_bib0044","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0045","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200 Mg linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0046","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific t-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0047","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-024-01018-6","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.05.002_bib0048","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.002_bib0049","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0051","series-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","author":"Zhang","year":"2023"},{"key":"10.1016\/j.clml.2024.05.002_bib0052","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967676.59550.94","article-title":"S191 pivotal PHASE 2 monumental-1 results of talquetamab (TAL), a GPRC5DXCD3 bispecific antibody (BSAB), for relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Touzeau","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.05.002_bib0053","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.clml.2024.05.002_bib0054","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0055","doi-asserted-by":"crossref","unstructured":"Schinke C.D., Touzeau C., Minnema M., et al. 8036 poster session pivotal phase 2 monumental-1 results of talquetamab (Tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.8036"},{"key":"10.1016\/j.clml.2024.05.002_bib0056","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0057","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (Tal) + daratumumab (Dara) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2024.05.002_bib0058","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"S180 RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: preliminary results from a first-in-human trial","volume":"6","author":"Riley","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.05.002_bib0059","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.05.002_bib0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0061","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2024.05.002_bib0062","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0063","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0064","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.05.002_bib0066","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016 NCNN, clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2024.05.002_bib0067","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.002_bib0068","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1002\/ajh.26766","article-title":"Prevention of infections including vaccination strategies in multiple myeloma","volume":"98","author":"Ludwig","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.05.002_bib0069","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.05.002_bib0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaoncol.2021.5942","article-title":"Neutralizing antibody testing in patients with multiple myeloma following COVID-19 vaccination","volume":"8","author":"Terpos","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2024.05.002_bib0071","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1097\/HS9.0000000000000764","article-title":"Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy","volume":"6","author":"Ntanasis-Stathopoulos","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.05.002_bib0072","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:28:00Z","timestamp":1724473680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001757"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}